RT Journal Article
SR Electronic
T1 Alterations in the hepatic microenvironment following direct-acting antiviral therapy for chronic hepatitis C
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2025.02.17.25321289
DO 10.1101/2025.02.17.25321289
A1 Millian, Daniel E.
A1 Arroyave, Esteban
A1 Wanninger, Timothy G.
A1 Krishnan, Santhoshi
A1 Bao, Daniel
A1 Zhang, Jared R.
A1 Rao, Arvind
A1 Spratt, Heidi
A1 Ferguson, Monique
A1 Chen, Vincent
A1 Stevenson, Heather L.
A1 Saldarriaga, Omar A.
YR 2025
UL http://medrxiv.org/content/early/2025/02/18/2025.02.17.25321289.abstract
AB Background and aims. The first direct-acting antivirals (DAAs) to treat the viral hepatitis C (HCV) became available in 2011. Despite numerous clinical studies of patient outcomes after treatment, few have evaluated changes in the liver microenvironment. Despite achieving sustained virologic response (SVR), patients may still experience adverse outcomes like cirrhosis and hepatocellular carcinoma. By comparing gene and protein expression in liver biopsies collected before and after treatment, we sought to determine whether specific signatures correlated with disease progression and adverse clinical outcomes. Methods. Biopsies were collected from 22 patients before and after DAA treatment. We measured ∼770 genes and used multispectral imaging with custom machine learning algorithms to analyze phenotypes of intrahepatic macrophages (CD68, CD14, CD16, MAC387, CD163) and T cells (CD3, CD4, CD8, CD45, FoxP3). Results. Before DAA treatment, patients showed two distinct gene expression patterns: one with high pro-inflammatory and antiviral gene expression and another with weaker expression. Patients with adverse outcomes exhibited significantly (p<0.05) more inflammatory activity and had more advanced fibrosis stages in their baseline biopsies than those with liver disease resolution. Patients who achieved SVR had significantly decreased liver enzymes, reduced inflammatory scores, and restored type 1 interferon pathways similar to controls. However, after DAA treatment, patients with persistently high gene expression (67%, pre-hot) still had significantly worse outcomes (p<0.049) despite achieving SVR. A persistent lymphocytic infiltrate was observed in a subset of these patients (76.5%). After therapy, anti-inflammatory macrophages (CD16+, CD16+CD163+, CD16+CD68+) increased, and T cell heterogeneity was more pronounced, showing a predominance of helper and memory T cells (CD3+CD45RO+, CD4+CD45RO+, CD3+CD4+CD45RO+). Conclusions. Patients who have more inflamed livers and more advanced fibrosis before DAA treatment should be closely followed for the development of adverse outcomes, even after achieving SVR. We can enhance patient risk stratification by integrating gene and protein expression profiles with clinical data. This could identify those who may benefit from more intensive monitoring or alternative therapeutic approaches, inspiring a new era of personalized patient care.Lay Summary Direct-acting antiviral (DAA) therapy has dramatically improved the treatment of chronic HCV, making it curable for most people. This study determined gene and protein expression differences in the liver before and after treatment of HCV. These results will lead to a deeper understanding of the changes in the hepatic immune microenvironment with and without the virus present in the liver in hopes of improving patient surveillance, prognosis, and outcome in the future.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors gratefully acknowledge the financial support provided by their grant funding sources. O.A.S., E.A, and H.L.S. were partially supported by an R01 from NIDDK (1R01DK125730-01A1-4). O.A.S. and H.S.L. were additionally supported by a Moody Endowment Grant (2014-07; LIME 19016). Preliminary optimization studies were partly funded by the National Center for Advancing Translational Services Clinical and Translational Science Awards Grant NCATS CTSA Grant KL2 Scholars Program (KL2TR001441-06). The acquisition of the Vectra 3 microscope was made possible through funding from the UT Systems Faculty Science and Technology Acquisition and Retention (STARs) Program. A.R. and S.K. were supported by CCSG Bioinformatics Shared Resource 5 P30 CA046592, a gift from Agilent Technologies, and a Precision Health Investigator award from U-M Precision Health. The NCI Grant R37-CA214955 partially supported S.K. and A.R. S.K. and A.R. were also partially supported by The University of Michigan (U-M) startup institutional research funds. S.K. and A.R. were also supported by a Research Scholar Grant from the American Cancer Society (RSG-16-005-01).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board approved this work at the University of Texas Medical Branch (IRB protocol #:13-0511).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data pertinent to this study are either included within the main article or provided as supplementary materials.Abbreviations:HCVhepatitis C virusDAAdirect-acting antiviralSVRsustained virologic responsePOSTpost-daa treatmentPREpre-daa treatmentHCChepatocellular carcinomaIFNinterferonHIVhuman immunodeficiency virusUTMBuniversity of Texas medical branchIRBinstitutional review boardCAPcollege of American pathologistMHAImodified hepatitis activity indexALTalanine aminotransferaseASTaspartate aminotransferaseALPalkaline phosphataseCLIAclinical laboratory improvement amendmentsFFPEformalin-fixed, paraffin-embeddedRNAribonucleic acidRCCresource compiler filesPCAprincipal component analysisDEGdifferentially expressed genesROIsregions of interestANOVAanalysis of varianceDAPI4′,6-diamidino-2-phenylindoleJAKjanus kinaseSTATsignal transducer and activation of transcriptionBMIbody mass indexTNFtumor necrosis factorTGFBtransforming growth factor betaMHCmajor histocompatibility complexNKCnatural killer cellsISGinterferon-stimulated genesIFIinterferon inducible proteinMXmixovirus resistanceTIFFtagged image file formatH&Ehematoxylin and eosinTSNEt-distributed stochastic neighbor embeddingMAITmucosal-associated invariant T cellsHAARThighly active antiretroviral therapyNLRPnucleotide-binding domain, leucine-rich-containing family, pyrin domain containingMASLDmetabolic dysfunction-associated steatotic liver diseaseMASHmetabolic dysfunction-associated steatohepatitisESLDend-stage liver diseasePTprothrombin timeINRinternational normalized ratioBYBenjamini-YekutieliSTRINGsearch tool for the retrieval of interacting genes/proteinsFDRfalse discovery ratesMCLMarkov cluster algorithmptpatientAIartificial intelligence